The Sức khỏe & Đời sống (Health & Life) Newspaper, in collaboration with Takeda Pharmaceuticals Vietnam Co., Ltd. and the Vietnam Society of Preventive Medicine, recently hosted a medical symposium titled “Dengue Fever: Unpredictable Developments in Vietnam” ahead of ASEAN Dengue Day (June 15). During the panel, leading public health officials warned that Dengue transmission is actively breaking historical epidemiological patterns, expanding its geographic reach, and placing a heavy burden on both critical care units and household economies.
The documented shifting epidemiological metrics, clinical-economic burdens, and new integrated prevention strategies feature:
-
Epidemiological Anomalies and the Dominance of High-Risk Serotypes:
-
Exponential Case Surge: Statistical data from the General Department of Preventive Medicine (Ministry of Health) reveals that in the first 5 months of 2026 alone, Vietnam recorded over 50,000 Dengue cases—a profound 2.5-fold increase compared to the same period last year. This surge stems from an anomalous 2025 outbreak cycle that failed to subside during the winter months (remaining highly active through November and December) due to unseasonable hot, humid, and rainy weather conditions driving vector multiplication.
-
Shortened Cycles and Serotype Shifts: The structural outbreak cycles are compressing compared to the historical baseline of 150.000 annual cases. Crucially, surveillance networks indicate that the DENV-2 serotype has achieved clear dominance across active transmission chains, drastically escalating the risk of severe clinical manifestations. Furthermore, the geographical footprint of the disease has expanded nationwide, routinely impacting Northern provinces that were historically less vulnerable.
-
-
Demographic Shifts, Clinical Traps, and Economic Hardships:
-
Eradication of Age Boundaries: Dengue has officially shifted away from being primarily a pediatric disease. While over a decade ago, 60% to 70% of cases in the Southern region were concentrated in children under 15, the current epidemiological breakdown shows an equal 50/50 split between pediatric patients and adults over 15.
-
The Critical “Deceptive” Window: Clinicians emphasized that public complacency remains a critical barrier to care. Dengue exhibits a highly deceptive clinical progression: between day 3 and day 5, as the patient’s fever subsides and they feel improved, the disease enters its most lethal phase, frequently triggering sudden Dengue Shock Syndrome (DSS), severe internal hemorrhaging, and multi-organ failure.
-
Financial Strains and Long-Term Sequelae: Critical cases requiring mechanical ventilation and continuous renal replacement therapy (CRRT) generate severe financial strain, with intensive care costs ranging from hundreds of millions to up to 500–600 million VND per patient. Furthermore, surviving patients frequently present with long-term post-Dengue sequelae, including cognitive decline, chronic insomnia, depression, alopecia, and visual impairment.
-
-
Scientific Innovations and the 2030 Zero-Mortality Roadmap:
-
While legacy vector control models (eliminating standing water and mosquito breeding sites) remain the baseline first line of defense, the World Health Organization (WHO) and the Ministry of Health are moving toward leveraging technology and Artificial Intelligence (AI) to pioneer early warning systems utilizing climate data.
-
Crucially, Vietnam has formally approved a novel Dengue vaccine candidate. The Ministry of Health is currently coordinating localized pilot vaccination programs across targeted high-burden territories to evaluate real-world feasibility. This field data will serve as the scientific foundation for potentially integrating the vaccine into the National Expanded Program on Immunization (EPI), directly supporting the WHO’s global mandate to achieve zero Dengue-mediated fatalities by 2030.
-